- Q1 2024 Embla Medical hf Earnings Call TranscriptApr 23, 2024kr30.7 (+1.99%)Earnings
- Q4 2023 Ossur hf Earnings Call TranscriptJan 30, 2024kr29.65 (+4.40%)Earnings
- Q3 2023 Ossur hf Earnings Call TranscriptOct 24, 2023kr29.3 (+2.99%)Earnings
- Q2 2023 Ossur hf Earnings Call TranscriptJul 25, 2023kr32.4 (+1.73%)Earnings
- Q1 2023 Ossur hf Earnings Call TranscriptApr 25, 2023kr30.75 (-1.76%)Earnings
- Ossur hf Corporate Analyst Meeting TranscriptMar 30, 2023
- Q4 2022 Ossur hf Earnings Call TranscriptJan 31, 2023Earnings
- Q3 2022 Ossur hf Earnings Call TranscriptOct 25, 2022kr32.95 (-1.79%)Earnings
- Q2 2022 Ossur hf Earnings Call TranscriptJul 21, 2022kr31.5 (+5.00%)Earnings
- Preliminary Q2 2022 Ossur hf Earnings Call TranscriptJul 18, 2022kr29.6Earnings
- Q1 2022 Ossur hf Earnings Call TranscriptApr 26, 2022kr36.4 (-5.45%)Earnings
- Q4 2021 Ossur hf Earnings Call TranscriptFeb 01, 2022kr40.6 (+4.10%)Earnings
- Q3 2021 Ossur hf Earnings Call TranscriptOct 26, 2021kr43.2Earnings
- Q2 2021 Ossur hf Earnings Call TranscriptJul 22, 2021kr48 (+1.27%)Earnings
- Q1 2021 Ossur hf Earnings Call TranscriptApr 27, 2021kr47.25 (+2.05%)Earnings
- Q4 2020 Ossur hf Earnings Call TranscriptFeb 02, 2021kr46.25 (+0.22%)Earnings
- Q3 2020 Ossur hf Earnings Call TranscriptOct 27, 2020kr42 (-2.33%)Earnings
- Q2 2020 Ossur hf Earnings Call TranscriptJul 23, 2020kr44.3 (+0.23%)Earnings
- Q1 2020 Ossur hf Earnings Call TranscriptApr 30, 2020kr43.65 (+1.51%)Earnings
- Q4 2019 Ossur hf Earnings Call TranscriptFeb 04, 2020kr49.55 (-0.10%)Earnings
- Full Year 2019 Ossur hf Guidance Call TranscriptJan 14, 2020
- Q3 2019 Ossur hf Earnings Call TranscriptOct 22, 2019kr45.5 (+1.11%)Earnings
- Q2 2019 Ossur hf Earnings Call TranscriptJul 25, 2019kr45.95 (+5.88%)Earnings
- Q1 2019 Ossur hf Earnings Call TranscriptApr 30, 2019kr37.3 (+5.97%)Earnings
Preliminary Q2 2022 Ossur hf Earnings Call Transcript
&
Thank you very much. I would like to welcome you to this conference call where we will begin by going through our revised guidance for 2022 and then sort of a brief overview of our preliminary results for quarter 2. And then we can go into a Q&A session afterwards.
Our revised organic growth guidance for 2022 is now 4% to 6%, previously 6% to 9% for the full year. And our revised guidance for EBITDA margin before special items is now 18% to 20% for 2022, adjusted from our previous estimate of 20% to 21%. Currently, we estimate that organic sales growth and EBITDA margin before special items will be around the middle of this new guidance range, and other guidance parameters are unchanged.
Now although sales have been strong in many key markets in EMEA and APAC in the first half of the year, sales have been slower than what we expected in Americas. COVID-19 related lockdowns in China have also impacted our sales in that important market. And then as we previously communicated, also sales to
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust.png)